AI Article Synopsis
- - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are transformative drugs for diabetes management, known for their heart and kidney protective effects.
- - There’s potential for SGLT2i to be beneficial in treating COVID-19 due to their ability to reduce inflammation and stress in the body, addressing issues similar to those seen in diabetes.
- - However, SGLT2i may carry risks, like euglycemic diabetic ketoacidosis, so ongoing clinical trials are necessary to determine if their benefits in COVID-19 treatment outweigh the risks.
Article Abstract
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering agents which have changed the landscape of diabetes therapy, due to their remarkable cardiorenal protective properties. The attack of severe acute respiratory syndrome coronavirus 2 on the heart and kidneys shares similarities with diabetes; therefore, the notion that SGLT2i might have a role in the future management of Coronavirus Disease 2019 (COVID-19) is based on a solid pathophysiological hypothesis. SGLT2i have been proved to decrease the expression of proinflammatory cytokines, ameliorate oxidative stress and reduce sympathetic activity, thus resulting in downregulation of both systemic and adipose tissue inflammation. On the other hand, they have been linked to an increased risk of euglycemic diabetic ketoacidosis. Therefore, the efficacy and safety of SGLT2i in COVID-19 are still debatable and remain to be clarified by ongoing randomized trials, to assess whether the benefits of treatment with these drugs outweigh the potential risks.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942520 | PMC |
| http://dx.doi.org/10.1007/s11096-021-01256-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!